resultsread-only vieweressays

frontiers / frontier

Anti-amyloid translation in Alzheimer's disease

CC-BY-4.0vfr_5076e7b3ff8e6b0f

id: vfr_5076e7b3ff8e6b0f
license: CC-BY-4.0
findings: 144
accepted core: 44
contested: 9

144

findings

links

125

sources

147

evidence

contested

0.63

avg conf

frontiers / frontier

Anti-amyloid translation in Alzheimer's disease

CC-BY-4.0vfr_5076e7b3ff8e6b0f

id: vfr_5076e7b3ff8e6b0f
license: CC-BY-4.0
findings: 144
accepted core: 44
contested: 9

144

findings

links

125

sources

147

evidence

contested

0.63

avg conf

Source record

back to sources

US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.

id: vs_5588c5efb07284af
frontier: Anti-amyloid translation in Alzheimer's disease
type: paper

source boundary

frontier-owned

declared

A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.

finding bindings

record context

1 findings

Findings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.

evidence atoms

materialized

1 atoms

Evidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.

review context

inspectable

2 events

2 reviewable changes and 0 evaluations are attached through this source or its findings.

Locator and citation

external source

locator

doi:10.1021/acs.jmedchem.6b00307

doi

10.1021/acs.jmedchem.6b00307

imported

2026-05-06T03:57:50.975685+00:00

extraction mode

manual_curation

authors

reviewer:will-blair-bot

Caveats

No source-specific caveats are recorded.

Bound findings

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.
therapeutic · vf_a74a1efa53aa4ed8

Evidence atoms

vea_35b5a12f0cb3aec2observational · supports
Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

Review, event, and evaluation records

events

vev_945fd8fbbaac1b39finding.reviewed
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_df20b2cdc051c871finding.asserted
Manual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06

reviewable changes

vpr_6f700e042277aa81finding.add
Manual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7029395b74841f83finding.review
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06

evaluations

No evaluation rows are attached.

Source record

back to sources

US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.

id: vs_5588c5efb07284af
frontier: Anti-amyloid translation in Alzheimer's disease
type: paper

source boundary

frontier-owned

declared

A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.

finding bindings

record context

1 findings

Findings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.

evidence atoms

materialized

1 atoms

Evidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.

review context

inspectable

2 events

2 reviewable changes and 0 evaluations are attached through this source or its findings.

Locator and citation

external source

locator

doi:10.1021/acs.jmedchem.6b00307

doi

10.1021/acs.jmedchem.6b00307

imported

2026-05-06T03:57:50.975685+00:00

extraction mode

manual_curation

authors

reviewer:will-blair-bot

Caveats

No source-specific caveats are recorded.

Bound findings

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.
therapeutic · vf_a74a1efa53aa4ed8

Evidence atoms

vea_35b5a12f0cb3aec2observational · supports
Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

Review, event, and evaluation records

events

vev_945fd8fbbaac1b39finding.reviewed
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_df20b2cdc051c871finding.asserted
Manual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06

reviewable changes

vpr_6f700e042277aa81finding.add
Manual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7029395b74841f83finding.review
Accepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06

evaluations

No evaluation rows are attached.

vs_5588c5efb07284af · source

Search Canopus

declared

1 findings

1 atoms

2 events

Bound findings

Evidence atoms

Review, event, and evaluation records

declared

1 findings

1 atoms

2 events

Bound findings

Evidence atoms

Review, event, and evaluation records